Italia markets closed

Zynerba Pharmaceuticals, Inc. (0M40.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,3607+0,2507 (+22,59%)
Alla chiusura: 05:27PM BST
Schermo intero
Chiusura precedente1,1100
Aperto1,3180
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,3180 - 1,3650
Intervallo di 52 settimane1,3180 - 1,3650
Volume205
Media VolumeN/D
Capitalizzazione511.145
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-0,9620
Prossima data utili10 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

    Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing resources on orphan neuropsychiatric disorders, FXS and 22q $62.5 million in cash and cash equivalents at June 30, 2022; Cash runway through the end of 2023 / early 2024 DEVON, Pa., Aug. 10, 2022 (GLOBE N

  • GlobeNewswire

    Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference

    DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present an overview and update of the Company at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 9:00 a.m. ET at the InterContinental Boston

  • GlobeNewswire

    Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

    DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced it has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Under the terms of the agreement, Zynerba will have the right in its sole discretion, but not the obligation, to s